Viridian Therapeutics presents phase 3 data: what it means for Viridian Therapeutics stock

Published on 10/18/2026 at 13:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elegrobart reached 54 percent responders versus 18 percent for placebo on October 15, 2026. Viridian Therapeutics stock has USD 2.2 billion market value.

Clinical data and financial scale

On October 15, 2026, REVEAL-1 showed 54 percent responders versus 18 percent for placebo.
Second-quarter 2026 revenue was USD 284,000, while the GAAP net loss reached USD 127.12 million.
RBC Capital maintained its Buy rating and set a USD 38.00 target on October 8, 2026.

VRDN, US92790C1045, Illustration mit AI erstellt.

Viridian Therapeutics (ISIN US92790C1045) presented phase 3 REVEAL-1 data on October 15, 2026, showing a 54 percent proptosis responder rate for elegrobart given every four weeks versus 18 percent for placebo, according to Ophthalmology Management. The trial enrolled 132 adults with active thyroid eye disease.

What does the trial mean for treatment?

The result gives Viridian a quantified basis for its planned subcutaneous treatment strategy. The company is developing elegrobart as an investigational insulin-like growth factor 1 receptor therapy, with dosing every four or eight weeks and a potential autoinjector route described in the October 15 report.

Three events shaped the story

On October 2, 2026, LifeSci Capital maintained a Buy rating and a USD 35.00 target for Viridian, according to Markets Insider. On October 8, 2026, RBC Capital maintained its Buy rating and set a USD 38.00 target. The October 15, 2026, REVEAL-1 presentation then supplied the latest clinical figure, with the 54 percent response rate against 18 percent for placebo.

Revenue stays small beside losses

Viridian's commercial scale remains limited relative to its development spending. For the quarter ended June 30, 2026, revenue was USD 284,000 and the GAAP net loss was USD 127.12 million, compared with USD 75,000 of revenue and a USD 100.74 million loss in the year-earlier quarter, according to Markets Insider. The company therefore remains dependent on clinical execution and future product launches rather than current revenue.

Which dates come next?

Viridian is scheduled to report September 2026 results on November 4, 2026, according to MetaCap. The company also plans a biologics license application for elegrobart in the first quarter of 2027, as reported in the October 14, 2026, coverage by Ophthalmology Times.

Market value and development risk

Viridian's market capitalization was USD 2.2 billion as of October 16, 2026, while its 52-week range was USD 13.18 to USD 34.29. The combination of a late-stage clinical asset, a planned regulatory filing and a USD 127.12 million quarterly GAAP loss leaves the stock tied closely to trial progress and commercial execution.

The further course of trading is shown by the continuously updated real-time quote of Viridian Therapeutics stock.